Ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication of pharmacological ovarian stimulation. It is seen in approximately 2 % of all IVF cycles. The prevalence of moderate to severe OHSS ranges from 1 to 10 % in major IVF programs. Severe forms complicate 1 % of IVF cycles and are characterized by massive ovarian enlargement together with a fluid shift into ext...

The use of IVF has risen dramatically over the past 10 years and with this the complications of such treatments have also risen. One such complication is ovarian hyperstimulation syndrome with which patients can present acutely to hospital with shortness of breath. On admission, a series of blood tests are routinely performed, including the d-dimer. We present a case of a 41-year-old lady who h...

The ovarian hyperstimulation syndrome (OHSS) is a potentially fatal condition with a pathophysiology that is not clearly understood. A shift in fluid from the extravascular space occurs, thought to be induced by cytokines and/or vascular endothelial growth factor. Human chorionic gonadotrophin (hCG), exogenous or endogenous, seems to be the triggering mechanism, resulting in early and late deve...

there are currently ‎many different protocols in use for controlled ovarian hyperstimulation (coh), but the optimal method has ‎not yet been determined. to compare the outcome of coh using ‎clomiphene citrate (cc) versus cc plus human menopausal gonadotropin (hmg) in conjunction with intrauterine insemination (iui), we studied 117 infertile couples‎. iui with cc was used in 92 cycles ‎(group a)...

Human chorionic gonadotrophin (HCG) may substitute FSH to complete follicular growth in IVF cycles. This may be useful in the prevention of ovarian hyperstimulation syndrome. Relevant studies were identified on Medline. To evaluate outcomes, a meta-analysis of low-dose HCG-supplemented IVF cycles versus non-supplemented ones was performed with data from 435 patients undergoing IVF who were admi...

The Ovarian Hyperstimulation Syndrome (OHSS) represents one of the biggest nightmares of all physicians involved in Assisted Reproductive Technologies (ART). Every year, several hundreds of women are hospitalized and to date several deaths have been reported. The pivotal event in the development of OHSS is the disruption of capillary integrity that results in leakage of intravascular fluid and ...

BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is considered to be an iatrogenic complication of ovulation induction therapy. However, OHSS may rarely be associated with spontaneous ovulatory cycles, usually in multiple or molar gestations or hypothyroidism. Clinical manifestations vary and may be potentially fatal in severe cases. CASE REPORT A 28-year-old primigravid, with no history o...

Ovarian hyperstimulation syndrome (OHSS) is a rare and serious complication of hormonal treatment for induction of ovulation. Haemoconcentration owing to the large fluid shift from the intravascular to the peritoneal cavity resulting in increased blood viscosity that can lead to arterial and venous occlusion. Thromboembolic stroke, cerebral venous thrombosis and systemic arteriovenous thrombosi...

Ovarian hyperstimulation syndrome (OHSS) is a complication that occurs in the luteal phase of an induced hormonal cycle. In most cases, the symptoms are self-limited, and spontaneous regression occurs [1]. Mild manifestations of OHSS include transient lower abdominal discomfort, nausea, vomiting, diarrhea, and abdominal distension. Life-threatening OHSS can progress to adult respiratory distres...

The GnRH analogue (agonist and antagonist GnRH) changed ovarian stimulation. On the one hand, it improved chances of pregnancy to obtain more oocytes and better embryos. This leads to an ovarian hyper-response, which can be complicated by the ovarian hyperstimulation syndrome (OHSS). On the other hand, the GnRH analogue can prevent the incidence of OHSS: GnRH antagonist protocols, GnRH agonist ...